Fasoracetam (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fasoracetam" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
274th place
309th place
11th place
8th place
6,219th place
4,029th place
low place
low place
3rd place
3rd place
5,344th place
3,420th place
406th place
258th place
18th place
17th place
low place
low place
6,658th place
4,027th place

books.google.com

doi.org

  • Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.
  • Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). "Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs". Current Pharmaceutical Design. 8 (2): 125–138. doi:10.2174/1381612023396582. PMID 11812254.
  • Connolly JJ, Glessner JT, Elia J, Hakonarson H (September 2015). "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Therapeutic Innovation & Regulatory Science. 49 (5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
  • Nageye F, Cortese S (July 2019). "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Review of Neurotherapeutics. 19 (7): 707–717. doi:10.1080/14737175.2019.1628640. PMID 31167583.
  • Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, et al. (January 2018). "Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling". Nature Communications. 9 (1): 4. Bibcode:2018NatCo...9....4E. doi:10.1038/s41467-017-02244-2. PMC 5770454. PMID 29339723.

harvard.edu

ui.adsabs.harvard.edu

ijest.org

legislation.gov.au

mednet-communities.net

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.
  • Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). "Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs". Current Pharmaceutical Design. 8 (2): 125–138. doi:10.2174/1381612023396582. PMID 11812254.
  • Connolly JJ, Glessner JT, Elia J, Hakonarson H (September 2015). "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Therapeutic Innovation & Regulatory Science. 49 (5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
  • Nageye F, Cortese S (July 2019). "Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD". Expert Review of Neurotherapeutics. 19 (7): 707–717. doi:10.1080/14737175.2019.1628640. PMID 31167583.
  • Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, et al. (January 2018). "Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling". Nature Communications. 9 (1): 4. Bibcode:2018NatCo...9....4E. doi:10.1038/s41467-017-02244-2. PMC 5770454. PMID 29339723.

ncbi.nlm.nih.gov

prnewswire.com

seekingalpha.com

semanticscholar.org

api.semanticscholar.org

  • Malykh AG, Sadaie MR (February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767. S2CID 12176745.

soton.ac.uk

eprints.soton.ac.uk

springer.com

adisinsight.springer.com